Search
Hydrocortisone butyrate
go.drugbank.com/drugs/DB14540ApprovedVet approvedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersHydrocortisone probutate
go.drugbank.com/drugs/DB14543ApprovedVet approvedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersTilidine
go.drugbank.com/drugs/DB13787InvestigationalMixtures: TILIDIN HEXAL COMP D-PUMPE, TILIDIN 100/8 RETARD 1A PHCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics in various chemical pathways ...
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigationalPancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The amylases are enzymes that help in the chemical proce...
Synonyms: 1,4-alpha-D-Glucan glucanohydrolaseMixtures: KREON MIKRO 5000 IU MINIMIKROSFER,Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedThe average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449].
Amibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalRipasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in S...
Azidocillin
go.drugbank.com/drugs/DB08795ExperimentalAzidocillin is a penicillin antibiotic similir to ampicillin.
Synonyms: D-(−)-(α-azidobenzyl)penicillinIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalAlthough non-dihydropyridine calcium channel blockers and beta blockers also effectively lower heart rate, they exhibit adverse events due to their negative ionotropic effects. … FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates